Summary
Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4′ deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks. There were no clinical responses in this group of patients. Toxicities were infrequent with neutropenia and thrombocytopenia being dose limiting. Nausea and vomiting occurred in only 4 patients. We conclude that 4′ deoxydoxorubicin is an inactive drug in this patient population and does not warrant further investigation in this disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bertazzoli C, Sammartini U, Tosana MG, Ballerini L, Bellini O: Screening for cardiotoxic properties. In: Anthracycline antibiotics in cancer chemotherapy. FM Muggia, CW Young, SK Carter (eds) Martinus Nijhoff, pp 306–316, 1982
Casazza AM: Experimental evaluation of anthracycline analogs. Cancer Treat Rep 63: 835–844, 1979
Ferrari L, Rossi A, Brambilla C, Villani F, Crippa F, Bonadonna G: Phase I study with 4′ deoxydoxorubicin. Invest New Drugs 2 (3): 287–295, 1984
Rozencweig M, Crespeigne N, Kenis Y: Phase I trial with 4′ deoxydoxorubicin (esorubicin). Invest New Drugs 1 (4): 309–313, 1983
de Palo GM, De Lena M, Di Re F, Luciani L, Valagussa P, Bonadonna G: Melphalan versus Adriamycin in the treatment of advanced carcinoma of the ovary. Surg Gynecol Obstet 141: 899–902, 1975
Hubbard SM, Barkes P, Young RC: Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy. Cancer Treat Rep 62: 1375–1377, 1978
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (6): 649–655, 1982
Edwards CL, Herson J, Gershenson DM, Copeland LJ, Wharton JT: A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin and cyclophosphamide in advanced ovarian cancer. Gynecol Oncol 15: 261–277, 1983
Piccart MJ, Speyer JL, Wernz JC, Noumoff J, Beller U, Beckman M, Dubin N, Demopoulos R, Muggia F: Advanced ovarian cancer: Three-year results of a 6–8 month, 2-drug cisplatin-containing regimen. Eur J Cancer Clin Oncology 23 (6): 631–641, 1987
Stuart CGE, Jeffries M, Stuart JL, Anderson RJ: The changing role of “second-look” laparotomy in the management of epithelial carcinoma of the ovary. Am J Obstet Gynecol 142: 612–616, 1982
Bolis G, D'Incalci M, Gramellini F, Mangioni C: Adriamycin in ovarian cancer patients resistant to cyclophosphamide. Eur J Cancer 14: 1401–1402, 1978
Kavanagh JJ, Copeland LJ, Gershenson DM, Saul PB, Edwards CL: A phase II trial of 4-Demethoxydaunorubicin in refractory epithelial ovarian cancer. Gynecol Oncol 24 (1): 23–26, 1986
Hakes TB, Daghestani AN, Dougherty JB, Weiselbery L, Raymond V: Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma. Cancer Treat Rep 69 (5): 559–560, 1985
van Oosterom AT, Aapro MS, Carnino F, van der Burg ME, Pecorelli S, Rotmensz N, Dalessio O, Vermorken JB: Esorubicin in advanced ovarian epithelial cancer. A Phase II study of the EORTC Gynecological cancer cooperative group. Eur J Can Clin Oncol 24 (8): 1379–1380, 1988
Author information
Authors and Affiliations
Additional information
N. Colombo is a recipient of a fellowship from the American-Italian Foundation for Cancer Research.
Rights and permissions
About this article
Cite this article
Green, M.D., Speyer, J.L., Wernz, J.C. et al. Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer. Invest New Drugs 8, 333–336 (1990). https://doi.org/10.1007/BF00171850
Issue Date:
DOI: https://doi.org/10.1007/BF00171850